Skip to main content
Top
Published in: Annals of Surgical Oncology 8/2014

01-08-2014 | Colorectal Cancer

Nuclear Notch3 Expression is Associated with Tumor Recurrence in Patients with Stage II and III Colorectal Cancer

Authors: Tsuyoshi Ozawa, MD, Shinsuke Kazama, MD, PhD, Takashi Akiyoshi, MD, PhD, Koji Murono, MD, Satomi Yoneyama, MD, PhD, Toshiaki Tanaka, MD, PhD, Junichiro Tanaka, MD, PhD, Tomomichi Kiyomatsu, MD, PhD, Kazushige Kawai, MD, PhD, Hiroaki Nozawa, MD, PhD, Takamitsu Kanazawa, MD, PhD, Hironori Yamaguchi, MD, PhD, Soichiro Ishihara, MD, PhD, Eiji Sunami, MD, PhD, Joji Kitayama, MD, PhD, Teppei Morikawa, MD, PhD, Masashi Fukayama, MD, PhD, Toshiaki Watanabe, MD, PhD

Published in: Annals of Surgical Oncology | Issue 8/2014

Login to get access

Abstract

Background

The importance of Notch signaling in colorectal cancer (CRC) tumorigenesis has been recently recognized. However, the significance of Notch3 expression and its association with Notch1 expression in CRC is unclear. In the present study, we investigated Notch1 and Notch3 expression in Stage II and III CRC to assess their association with clinicopathological characteristics.

Methods

The protein expression of Notch1 and Notch3 was examined using immunohistochemistry in 305 CRC specimens. Nuclear expression of Notch1 and Notch3 and their associations with clinicopathological characteristics and distant relapse-free survival (dRFS) were evaluated.

Results

Nuclear Notch1 was overexpressed in 37 % of specimen, and nuclear Notch3 in 38 %. Nuclear Notch3 expression correlated with tumor differentiation status (P = 0.0099). Nuclear expression of Notch1 and Notch3 was associated with tumor recurrence (P = 0.0311 and P = 0.0053, respectively). In multivariate analysis, nuclear Notch3 expression [hazard ratio (HR) = 1.71; 95 % confidence interval (CI), 1.06–2.78; P = 0.0271), lymph node metastasis, and venous involvement were independently correlated with dRFS. In subgroup analysis, nuclear Notch3 expression was strongly associated with dRFS in Stage II CRC (HR = 3.47; 95 % CI 1.44–9.22; P = 0.0055). Both nuclear Notch1 and Notch3 were positive in 67 specimens (22 %) and both were negative in 144 specimens (47 %). Coexpression of nuclear Notch1 and Notch3 had an additive effect toward poorer dRFS compared with a negative subtype (HR = 2.48; 95 % CI, 1.41–4.40; P = 0.0019).

Conclusions

Nuclear Notch3 expression might be a novel predictive marker for recurrence in Stage II and III CRC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Artavanis-Tsakonas S, Muskavitch MA. Notch: the past, the present, and the future. Curr Top Dev Biol. 2010;92:1–29.PubMedCrossRef Artavanis-Tsakonas S, Muskavitch MA. Notch: the past, the present, and the future. Curr Top Dev Biol. 2010;92:1–29.PubMedCrossRef
2.
go back to reference Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649–61.PubMedCrossRef Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649–61.PubMedCrossRef
3.
go back to reference Liu J, Fan H, Ma Y, et al. Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLoS One. 2013;8:e56141.PubMedCentralPubMedCrossRef Liu J, Fan H, Ma Y, et al. Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLoS One. 2013;8:e56141.PubMedCentralPubMedCrossRef
4.
go back to reference Mullendore ME, Koorstra JB, Li YM, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res. 2009;15:2291–301.PubMedCentralPubMedCrossRef Mullendore ME, Koorstra JB, Li YM, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res. 2009;15:2291–301.PubMedCentralPubMedCrossRef
5.
go back to reference Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65:8530–7.PubMedCrossRef Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65:8530–7.PubMedCrossRef
6.
go back to reference Park JT, Chen X, Tropè CG, et al. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177:1087–94.PubMedCentralPubMedCrossRef Park JT, Chen X, Tropè CG, et al. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177:1087–94.PubMedCentralPubMedCrossRef
8.
go back to reference Bellavia D, Checquolo S, Campese AF, et al. Notch3: from subtle structural differences to functional diversity. Oncogene. 2008;27:5092–8.PubMedCrossRef Bellavia D, Checquolo S, Campese AF, et al. Notch3: from subtle structural differences to functional diversity. Oncogene. 2008;27:5092–8.PubMedCrossRef
9.
go back to reference Chu D, Zhang Z, Zhou Y, et al. Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol. 2011;22:2440–7.PubMedCrossRef Chu D, Zhang Z, Zhou Y, et al. Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol. 2011;22:2440–7.PubMedCrossRef
10.
go back to reference Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med. 2004;14:779–86.PubMed Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med. 2004;14:779–86.PubMed
11.
go back to reference Serafin V, Persano L, Moserle L, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol. 2011;224:448–60.PubMedCrossRef Serafin V, Persano L, Moserle L, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol. 2011;224:448–60.PubMedCrossRef
12.
go back to reference Morikawa T, Kuchiba A, Qian ZR, et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012;19:1944–53.PubMedCentralPubMedCrossRef Morikawa T, Kuchiba A, Qian ZR, et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012;19:1944–53.PubMedCentralPubMedCrossRef
13.
14.
go back to reference Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125–30.PubMedCentralPubMedCrossRef Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125–30.PubMedCentralPubMedCrossRef
15.
go back to reference Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138:958–68.PubMedCentralPubMedCrossRef Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138:958–68.PubMedCentralPubMedCrossRef
16.
go back to reference Jorissen RN, Gibbs P, Christie M, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res. 2009;15:7642–51.PubMedCentralPubMedCrossRef Jorissen RN, Gibbs P, Christie M, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res. 2009;15:7642–51.PubMedCentralPubMedCrossRef
18.
go back to reference Yeasmin S, Nakayama K, Rahman MT, et al. Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol. 2010;117:409–16.PubMedCrossRef Yeasmin S, Nakayama K, Rahman MT, et al. Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol. 2010;117:409–16.PubMedCrossRef
19.
go back to reference Pierfelice TJ, Schreck KC, Dang L, et al. Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Res. 2011;71:1115–25.PubMedCentralPubMedCrossRef Pierfelice TJ, Schreck KC, Dang L, et al. Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Res. 2011;71:1115–25.PubMedCentralPubMedCrossRef
20.
go back to reference Doucas H, Mann CD, Sutton CD, et al. Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J Surg Oncol. 2008;97:63–8.PubMedCrossRef Doucas H, Mann CD, Sutton CD, et al. Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J Surg Oncol. 2008;97:63–8.PubMedCrossRef
21.
go back to reference Hornberger J, Lyman GH, Chien R, Meropol NJ. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health. 2012;15:1014–21.PubMedCrossRef Hornberger J, Lyman GH, Chien R, Meropol NJ. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health. 2012;15:1014–21.PubMedCrossRef
22.
go back to reference Zhang Y, Li B, Ji ZZ, Zheng PS. Notch1 regulates the growth of human colon cancers. Cancer. 2010;116:5207–18.PubMedCrossRef Zhang Y, Li B, Ji ZZ, Zheng PS. Notch1 regulates the growth of human colon cancers. Cancer. 2010;116:5207–18.PubMedCrossRef
23.
go back to reference Chu D, Li Y, Wang W, et al. High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol. 2010;17:1337–42.PubMedCrossRef Chu D, Li Y, Wang W, et al. High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol. 2010;17:1337–42.PubMedCrossRef
24.
go back to reference Chu D, Zhou Y, Zhang Z, et al. Notch1 expression, which is related to p65 Status, is an independent predictor of prognosis in colorectal cancer. Clin Cancer Res. 2011;17:5686–94.PubMedCrossRef Chu D, Zhou Y, Zhang Z, et al. Notch1 expression, which is related to p65 Status, is an independent predictor of prognosis in colorectal cancer. Clin Cancer Res. 2011;17:5686–94.PubMedCrossRef
25.
go back to reference Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: who is talking to whom about what? Circ Res. 2007;100:1556–68.PubMedCrossRef Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: who is talking to whom about what? Circ Res. 2007;100:1556–68.PubMedCrossRef
26.
go back to reference Sonoshita M, Aoki M, Fuwa H, et al. Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell. 2011;19:125–37.PubMedCrossRef Sonoshita M, Aoki M, Fuwa H, et al. Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell. 2011;19:125–37.PubMedCrossRef
Metadata
Title
Nuclear Notch3 Expression is Associated with Tumor Recurrence in Patients with Stage II and III Colorectal Cancer
Authors
Tsuyoshi Ozawa, MD
Shinsuke Kazama, MD, PhD
Takashi Akiyoshi, MD, PhD
Koji Murono, MD
Satomi Yoneyama, MD, PhD
Toshiaki Tanaka, MD, PhD
Junichiro Tanaka, MD, PhD
Tomomichi Kiyomatsu, MD, PhD
Kazushige Kawai, MD, PhD
Hiroaki Nozawa, MD, PhD
Takamitsu Kanazawa, MD, PhD
Hironori Yamaguchi, MD, PhD
Soichiro Ishihara, MD, PhD
Eiji Sunami, MD, PhD
Joji Kitayama, MD, PhD
Teppei Morikawa, MD, PhD
Masashi Fukayama, MD, PhD
Toshiaki Watanabe, MD, PhD
Publication date
01-08-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 8/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3659-9

Other articles of this Issue 8/2014

Annals of Surgical Oncology 8/2014 Go to the issue